• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ATRASENTAN Drug Record

  • Summary
  • Interactions
  • Claims
  • ATRASENTAN chembl:CHEMBL9194 Antineoplastic

    Alternate Names:

    A-127722
    ATRASENTAN

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    (0 More Sources)

    Publications:

    Nelson J et al., 2003, The endothelin axis: emerging role in cancer., Nat Rev Cancer
    Chichorro JG et al., 2006, Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs., Pain
    Cella D et al., 2006, Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?, Eur Urol
    Katz DA et al., 2006, Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics., Clin Pharmacol Ther
  • ATRASENTAN   EDNRA

    Interaction Score: 9.66

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name atrasentan, ABT-627,Xinlay

    PMIDs:
    12563310 16563629 16458417


    Sources:
    TdgClinicalTrial TTD

  • ATRASENTAN   SLCO1B1

    Interaction Score: 1.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16513443


    Sources:
    PharmGKB

  • TdgClinicalTrial: ATRASENTAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • PharmGKB: atrasentan

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Katz DA et al., 2006, Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics., Clin Pharmacol Ther

  • TTD: Atrasentan

    • Version: 2020.06.01

    Alternate Names:
    D0Y6UU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL9194

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21